Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 2.06
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'cheap' on P/E.
Data is available to registered users only
Target Price
Buy
Sell